Literature DB >> 24041840

The presence of hepatitis B core antibody is associated with more advanced liver disease in alcoholic patients with cirrhosis.

Mingyuan Zhang1, Ruihong Wu, Jing Jiang, Gerald Y Minuk, Junqi Niu.   

Abstract

BACKGROUND: Liver disease is more severe in patients with chronic hepatitis B virus (HBV) infections and alcohol-induced liver injury. Whether the same is true for alcoholic patients with cirrhosis who have recovered from previous HBV infections remains to be determined.
OBJECTIVES: To document the extent of liver disease in alcoholic patients with cirrhosis who test negative for hepatitis B surface antigen (HBsAg) and test positive for antibody to hepatitis B core antigen (anti-HBc).
METHODS: Two hundred fifty-four alcoholic patients with cirrhosis were divided into anti-HBc-positive (N = 171) and anti-HBc-negative (N = 83) cohorts. Demographic, clinical, and biochemical features were retrospectively analyzed. Prognostic scores and the prevalence of patients at high risk for short-term mortality were calculated. Logistic regression was used to identify factors associated with an increased risk for short-term mortality.
RESULTS: Jaundice was more common in the anti-HBc-positive cohort (32.2% vs. 18.1%, p = 0.02). This cohort also had higher serum bilirubin (70.9 vs. 50.4 μM/L, p = 0.03), prothrombin times (15.6 vs. 14.4 s, p = 0.01), MELD scores (8.5 vs. 4.6, p = 0.01), i-MELD scores (28.6 vs. 24.7, p = 0.03), MDF scores (14.2 vs. 6.8, p = 0.02) and ABIC scores (7.2 vs. 6.6, p = 0.01). In addition, anti-HBC-positive patients were more often at high risk for short-term mortality (40.4% vs. 26.5%, p = 0.03). Multivariate analysis identified anti-HBc-positive status (OR: 1.84; 95% CI: 1.10-3.36) and alcohol intake ≥150 g/day (OR: 2.01; 95% CI: 1.10-3.66) as independent risk factors for high risk of mortality.
CONCLUSION: The anti-HBc-positive state is associated with more advanced liver disease in alcoholic patients with cirrhosis. A prospective study including HBV-DNA testing and liver biopsies should be considered to validate and further elucidate these findings.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABIC; ACHE; ALB; ALP; ALT; AST; Alcoholic; Anti HBc; Anti-HBc; Anti-HBe; Anti-HBs; Anti-HCV; DALY; DBIL; GGT; HBV; HBeAg; HCC; Hepatitis B virus; INR and creatinine score; IQR; Liver cirrhosis; MDF; MELD; Maddrey's discriminant function; Mayo End-Stage Liver Disease; PLT; PT; Prognosis; TBIL; alanine aminotransferase; albumin; alkaline phosphatase; antibodies to hepatitis C virus; antibody to HBeAg; antibody to hepatitis B core antigen; antibody to hepatitis B surface antigen; aspartate aminotransferase; bilirubin; cholinesterase; direct bilirubin; disability-adjusted life-years; hepatitis B e antigen; hepatitis B virus; hepatocellular carcinoma; i-MELD; integrated-MELD; interquartile ranges; platelet; prothrombin time; total bilirubin; γ-glutamyltranspeptidase

Mesh:

Substances:

Year:  2013        PMID: 24041840     DOI: 10.1016/j.alcohol.2013.07.003

Source DB:  PubMed          Journal:  Alcohol        ISSN: 0741-8329            Impact factor:   2.405


  7 in total

Review 1.  Therapy for alcoholic liver disease.

Authors:  Maryconi M Jaurigue; Mitchell S Cappell
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

Review 2.  Update on Alcohol and Viral Hepatitis.

Authors:  Stefano Gitto; Giovanni Vitale; Erica Villa; Pietro Andreone
Journal:  J Clin Transl Hepatol       Date:  2014-12-15

3.  Prevalence of Serologic Hepatitis B Markers in Blood Donors From Puebla, Mexico: The Association of Relatively High Levels of Anti-Core Antibodies With the Detection of Surface Antigen and Genomic DNA.

Authors:  Francisca Sosa-Jurado; Nora Hilda Rosas-Murrieta; Belinda Guzman-Flores; Cintia Perez Zempoaltecalt; Ana Patricia Sanchez Torres; Leticia Ramirez Rosete; Maribel Bernal-Soto; Luis Marquez-Dominguez; Daniel Melendez-Mena; Miguel Angel Mendoza Torres; Maria Teresa Lopez Delgado; Julio Reyes-Leyva; Veronica Vallejo-Ruiz; Gerardo Santos-Lopez
Journal:  Hepat Mon       Date:  2016-06-01       Impact factor: 0.660

4.  Advancing Age and Comorbidity in a US Insured Population-Based Cohort of Patients With Chronic Hepatitis B.

Authors:  Mindie H Nguyen; Joseph K Lim; A Burak Ozbay; Jeremy Fraysse; Iris Liou; Nicole Meyer; Geoffrey Dusheiko; Stuart C Gordon
Journal:  Hepatology       Date:  2019-02-11       Impact factor: 17.425

5.  Neutrophil-to-Lymphocyte Ratio and Albumin: New Serum Biomarkers to Predict the Prognosis of Male Alcoholic Cirrhosis Patients.

Authors:  Mingyuan Zhang; Yu Zhang; Lili Liu; Mozumder Prithweeraj; Hongqin Xu; Ruihong Wu; Xiaoyu Wen; Junqi Niu
Journal:  Biomed Res Int       Date:  2020-12-21       Impact factor: 3.411

6.  Evaluation of impact of occult hepatitis B infection in chronic HCV-infected patients: A retrospective cohort study.

Authors:  Mohit Bhatia; Ekta Gupta; Manish C Choudhary; Ankur Jindal; Shiv Kumar Sarin
Journal:  J Lab Physicians       Date:  2018 Jul-Sep

7.  miR-103 promotes the metastasis and EMT of hepatocellular carcinoma by directly inhibiting LATS2.

Authors:  Li-Li Han; Xiao-Ran Yin; Shu-Qun Zhang
Journal:  Int J Oncol       Date:  2018-10-01       Impact factor: 5.650

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.